In addition, an elevated QPRT expression in the GMX1778-resistant HT1080 fibrosarcoma cell line and in the FK866-resistant CCRF-CEM leukemia cell line was the underlying resistance mechanism to these NAMPT inhibitors (through the activation of de novo NAD+ biosynthesis) [194,195]. The gene discussed is NAMPT; the disease is leukemia.